Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.82 USD | +3.15% | +5.94% | -3.62% |
Apr. 11 | Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target | MT |
Mar. 22 | B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.62% | 371M | |
+33.15% | 690B | |
+26.43% | 546B | |
-5.04% | 358B | |
+18.63% | 323B | |
+4.67% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+3.98% | 161B |
- Stock Market
- Equities
- HROW Stock
- News Harrow, Inc.
- Harrow Health's Eye Treatment Drug Vevye Now Available in US